Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Figure out how to Guarantee Your Dental Embeds Endure forever - 2Instructions to Pick the Best Album Rates for Your Investment funds
- 3Tablets: Upgrade Your Understanding Experience
- 4January’s full wolf supermoon and the Quadrantid meteor shower will start off the new year
- 5EU calls on Western Balkans to step up reforms for membership
- A 'Stranger Things' documentary covering the final season is on its way: Watch the trailer
- We may be witnessing the messy death of a star in real time
- Benihana is 60 years old. Gen Z is lining up.
- What really happens when 140 reality stars come face to face with their biggest fans
- Soldiers seize power in Guinea-Bissau and detain the president
- A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- Longtime United Launch Alliance CEO Tory Bruno resigns from space company. 'Finished the mission I came to do.'
- What is the 'Survivor 50' Challenge? Hidden immunity idols will be up for grabs in every U.S. state.
- Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
